文献速递神经肿瘤

LY6K通过CAV-1介导的ERK1/2信号增强促进胶质母细胞瘤致瘤性

LY6K promotes glioblastoma tumorigenicity via CAV-1-mediated ERK1/2 signaling enhancement.
PubMed 文献 · Neuro Oncol · 2020-01-01

研究探讨淋巴细胞抗原6复合物K(LY6K)在胶质母细胞瘤(GBM)中的机制。生物信息学分析显示LY6K高表达与GBM患者生存期缩短相关,LY6K在体外和体内均促进GBM细胞致瘤性,其机制为LY6K与CAV-1相互作用增强ERK1/2信号而非通过致癌受体酪氨酸激酶信号;DNA甲基化维持LY6K沉默,电离辐射诱导GSC中LY6K启动子去甲基化增加LY6K表达并导致放疗抵抗。作者认为LY6K是潜在膜靶点。

要点

  • LY6K高表达与GBM患者生存期缩短相关
  • LY6K通过CAV-1介导增强ERK1/2信号促进GBM致瘤性
  • 电离辐射诱导LY6K启动子去甲基化增加LY6K表达并促进GSC放疗抵抗

核心结论

  • LY6K促进GBM肿瘤生物学行为,作者认为LY6K是治疗GBM的潜在膜靶点。

研究设计与样本

  • 生物信息学数据挖掘分析LY6K表达与GBM临床结局的关系。
  • 使用患者来源的胶质瘤干细胞样细胞(GSCs)和U87细胞进行免疫印迹、免疫荧光染色、放射处理和原位GBM异种移植模型实验。

主要发现

  • LY6K表达升高与GBM患者生存期呈负相关。
  • LY6K在体外和体内均促进GBM细胞致瘤性。
  • LY6K与CAV-1相互作用介导ERK1/2信号增强,而非通过致癌受体酪氨酸激酶信号。
  • LY6K与细胞膜的关联对其致瘤功能至关重要。
  • DNA甲基化维持LY6K沉默,启动子低甲基化增加其表达。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Lymphocyte antigen 6 complex, locus K (LY6K) is a putative oncogene in various cancers. Elevated expression of LY6K is correlated with poor patient prognosis in glioblastoma (GBM). The aim of this study is to advance our understanding of the mechanism by which LY6K contributes to GBM tumor biology. METHODS: Bioinformatic data mining was used to investigate LY6K expression in relation to GBM clinical outcome. To understand the role of LY6K in GBM, we utilized patient-derived glioma stemlike cells (GSCs) and U87 cells and employed immunoblotting, immunofluorescent staining, radiation treatment, and orthotopic GBM xenograft models. RESULTS: Our results show that increased expression of LY6K inversely correlates with GBM patient survival. LY6K promotes tumorigenicity in GBM cells both in vitro and in vivo. The mechanism underlying this tumorigenic behavior is enhancement of extracellular signal-regulated kinase 1 and 2 (ERK1/2) signaling. Interestingly, we observed that tumor-promoting LY6K-ERK1/2 signaling is mediated by the interaction of LY6K with caveolin-1, rather than through oncogenic receptor tyrosine kinase-mediated signaling. Moreover, association of LY6K with the cell membrane is crucial for its tumorigenic functions. Finally, DNA methylation maintains LY6K silencing, and hypomethylation of the LY6K promoter increases its expression. In GSCs, ionizing radiation leads to demethylation of the LY6K promoter, thereby increasing LY6K expression and GSC resistance to radiation. CONCLUSIONS: Our study highlights the importance of the contribution of LY6K to GBM tumor biology and suggests LY6K as a potential membrane target for treating GBM.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Sastry NG, Wan X, Huang T, et al. LY6K promotes glioblastoma tumorigenicity via CAV-1-mediated ERK1/2 signaling enhancement. Neuro Oncol. 2020. PMID: 32055849. doi:10.1093/neuonc/noaa032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。